Metabolic dysfunction-associated steatotic liver disease

This study tests whether adding a Mediterranean-style meal delivery program to resmetirom therapy improves liver health more than resmetirom alone. It involves 120 adults with non-cirrhotic MASH who are starting resmetirom. Participants either receive the drug plus 10 medically t…

This study tests a procedure called pulsENDO that uses mild electric pulses to regenerate the lining of the first part of the small intestine (duodenum) in people recently diagnosed with type 2 diabetes. The goal is to see if this can help control blood sugar levels without needi…

This trial tests whether ursodeoxycholic acid (UDCA), a bile acid supplement, can speed up liver regeneration in adults receiving a living-donor liver transplant. Participants take UDCA or a placebo starting at least 10 days before surgery and continuing for 10 days after. Resear…

This study tests a procedure called pulsENDO that uses mild electric pulses to regenerate the lining of the duodenum (the first part of the small intestine). The goal is to improve blood sugar control and reduce fat buildup in the liver for people with type 2 diabetes and fatty l…

This clinical trial tests two experimental injections, HRS-4729 and HRS9531, in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. The study involves 160 participants who receive either the drug or a placebo for 52 we…

This Phase 3 trial tests whether the drug HSK31679 can safely improve liver health in 400 adults with MASH, a serious fatty liver disease. Participants will take either the drug or a placebo daily for about a year. The main goals are to see if the drug can reverse liver inflammat…

This study tests whether a traditional Chinese medicine formula called Chazhu Xiaoli Formula (CXD), combined with a very low-carb (ketogenic) diet, can reduce liver fat in people with MASLD (fatty liver disease). 135 adults aged 18-50 will be randomly assigned to one of three gro…

This study tests an experimental drug called ALN-CIDEB in 150 adults with MASH, a serious liver disease involving fat buildup and scarring. The goal is to see if the drug can reduce liver fat, injury, and scarring compared to a placebo. Participants will receive either the drug o…

This study tests whether a Chinese herbal capsule called Linzhi Jianghuang Fufang Huoxue Anshen (LJF) can safely reduce liver fat in people with non-alcoholic fatty liver disease. About 180 adults aged 18 to 65 with high liver fat will take the capsule or a placebo for 24 weeks. …

This Phase 2 trial tests a new drug called QL2401 in 132 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate liver scarring. Participants receive weekly injections of either QL2401 or a placebo for 48 weeks. The main goal is to see if the drug reduces…

This phase 2 trial tests whether daidzein, a natural compound found in soy, can improve liver tissue health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). 44 participants scheduled for gallbladder surgery will take daidzein capsules or receive st…

This study compares remote robotic liver surgery to local robotic surgery to see if the remote approach is just as safe and effective. About 148 adults with liver disease will be randomly assigned to one of the two types of surgery. Researchers will track complications, recovery,…

This study tests if the drug finerenone can prevent chronic kidney disease in adults with liver cirrhosis caused by fatty liver disease (MASLD) who also have fluid buildup in the belly (ascites). About 160 participants will receive either finerenone or spironolactone, along with …

This early-stage trial is testing a new drug called ACT500 in 24 people who have both fatty liver disease and chronic hepatitis B. The main goal is to check the drug's safety and how the body processes it at different doses. Participants will take ACT500 or a placebo daily, and r…

This study looks at whether exercising in the morning or evening makes a bigger difference in reducing liver fat for postmenopausal women with fatty liver disease. Sixty-three women will be placed into morning exercise, evening exercise, or a no-exercise group for 12 weeks. Resea…

This early study tests whether adding an experimental drug (CS0159) to a standard diabetes medication (semaglutide) can help people with fatty liver disease, obesity, and type 2 diabetes lose weight and improve their health. About 30 adults will take the combination or a placebo …

This study looks at whether combining a probiotic supplement with resistance exercise can help people with metabolic fatty liver disease (MAFLD/NAFLD). Researchers will measure changes in liver fat using MRI over 12 weeks. The goal is to find out which patients benefit most based…

This study tests whether giving a bile acid pill (TUDCA) to breastfeeding mothers with fatty liver disease can make their breast milk healthier for their babies. Eighty mother-infant pairs will be randomly assigned to receive TUDCA or a placebo for a short time after birth. The g…

This early-stage study tests a new drug called OPK-88006 in 30 people, first in healthy volunteers and then in those with MASH (a serious liver condition). The goal is to check safety, how the drug moves through the body, and early signs of liver improvement. Results will help de…

This study compares a traditional Mediterranean diet to a fully plant-based version in 50 adults with metabolic liver disease. Over 12 weeks, researchers will measure changes in liver fat, body weight, and overall health. The goal is to see if cutting out animal foods leads to be…

This study tests whether an artificial intelligence (AI) program that gives personalized diet and exercise advice can help people with non-alcoholic fatty liver disease (NAFLD) reduce liver fat more than standard lifestyle counseling. About 216 adults with NAFLD and overweight wi…

This phase 4 trial will test whether adding alogliptin to a standard two-drug regimen (pioglitazone and metformin) improves blood sugar control and liver health in 80 adults with type 2 diabetes and fatty liver disease. Participants must not have used diabetes medications in the …

This study tests a new drug called SNP-610 for people with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. About 80 adults will receive either the drug or a placebo for 3 months. The main goal is to see if SNP-610 lowers liver enzyme levels and reduces liver …

This study tests whether the DASH diet (a heart-healthy eating plan) can improve liver health in 88 children aged 11–18 with MASLD, a common fatty liver condition linked to obesity. Participants will follow the DASH diet for 12 weeks, and researchers will measure changes in liver…

This early-stage study tests a new oral drug called ACT500 in 24 adults with fatty liver disease (MASLD). The main goal is to check safety and how the drug moves through the body. Participants take one pill daily in different dose groups. The study does not aim to cure the diseas…

This study looks at whether a GLP-1 receptor agonist, a drug already used for diabetes and obesity, can improve fat buildup in the liver and blood in people with MASLD. Researchers will measure changes in fats, proteins, and genes in 30 participants who already take the drug. The…

This study tests a temporary device placed in the upper small intestine to help control type 2 diabetes and obesity. The implant stays for 6 months and is then removed. Researchers will check if it lowers blood sugar (HbA1c), helps with weight loss, and improves liver health in p…

This early-stage trial is testing a new drug called XTYW007 in healthy volunteers and people with high LDL cholesterol. The main goal is to check the drug's safety and how the body processes it, not yet to see if it treats non-alcoholic fatty liver disease (NAFLD). The study will…

This study looks at whether oral semaglutide, a drug already used for diabetes, can slow kidney disease in people who also have fatty liver disease. About 90 adults with both conditions will receive either the drug or standard care for 2 years. Researchers will track kidney funct…

This study tests whether empagliflozin, a drug used for diabetes, can help teens with non-alcoholic fatty liver disease (NAFLD) and obesity. Forty participants will take either the drug or a placebo for several weeks. The main goal is to see if the drug reduces liver fat measured…

This study will test two supplements — essential phospholipid and betaine HCL/L-glutamic acid — in 200 adults with metabolic fatty liver disease (MAFLD). The goal is to see which one reduces fat in the liver more effectively. Participants will be followed for a period to measure …

This study tests whether betaine, a natural substance found in the body, can reduce liver injury in people with MASH (a serious fatty liver disease). Seventy participants will take either betaine or placebo pills for 24 weeks, with follow-up for another 24 weeks. The main goal is…

This study tests whether a traditional Chinese herbal formula called Longqi Jiangzhi decoction can help treat non-alcoholic fatty liver disease in adults. Eighty participants will take either the herbal medicine or a placebo daily for eight weeks. Researchers will measure liver f…

This study tests whether taking rutin (a plant compound found in buckwheat and citrus) along with vitamin C can reduce inflammation and oxidative stress in people with metabolic fatty liver disease (MASLD). 120 adults will take either rutin plus vitamin C, vitamin C alone, or fol…

This study tests whether taking glycine, a natural amino acid, as a daily supplement for 26 weeks can improve liver health in people with metabolic fatty liver disease. Researchers will compare liver fat and blood markers between those taking glycine and those taking a placebo. T…

This study tests two blood products used to control bleeding during liver transplant surgery. It compares a newer product, Intercept Fibrinogen Complex, to standard cryoprecipitate. The goal is to see if the newer product works as well or better at stopping bleeding. The study wi…

This study tests whether eating only during an 8-hour window each day (time-restricted eating) can help people with fatty liver disease (MASLD) lose weight and body fat. 150 adults will follow this eating pattern for 3 months, with some also limiting fruit and vegetable intake to…

This early-phase study will test whether a drug called Henggliejin can improve fatty liver in 149 adults with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). Participants will take one tablet daily for 48 weeks. The main goal is to see if liver fibrosis risk scores …

This study tests whether diacerein, a drug made from a compound found in rhubarb, can help people with metabolic fatty liver disease. About 74 adults will receive either diacerein or a placebo for 24 weeks. The main goal is to see if the drug reduces fat in the liver, measured by…

This study tests whether empagliflozin (a diabetes drug) works better than statins for treating non-alcoholic fatty liver disease (NAFLD) and its more severe form, NASH. 400 obese, diabetic adults with NAFLD/NASH will take one of five drug combinations daily for 3 months. Researc…

This study tests whether adding a traditional Chinese medicine granule (Huazhi Rougan) to standard antibiotics can better treat both H. pylori infection and metabolic-associated fatty liver disease (MASH). About 286 adults with both conditions will receive either the herbal granu…

This study looks at whether a common blood test called FIB-4 can accurately predict liver fibrosis (scarring) in people with obesity. Researchers will compare FIB-4 results with liver stiffness measurements from a specialized scan (FibroScan) in 400 obese patients. If the blood t…

This study checks if a simpler way to collect blood samples works as well as the standard method for the HepQuant DuO liver test. The test involves drinking a natural substance and taking blood samples 20 and 60 minutes later. Researchers will compare different blood collection t…

This pilot study tests whether an AI tool called FibroX can help primary care providers better diagnose advanced liver fibrosis in people with MASLD, a common liver condition. Forty providers will review simulated patient cases, using either standard methods or FibroX, which give…

This study tests a near-infrared spectroscopy device that scans the liver with light to diagnose and measure fatty liver disease. Researchers aim to see if it can accurately detect fat levels above 5% and 30%, which are important for liver transplant decisions. The study will inc…

This study tests whether an artificial intelligence (AI) program can analyze routine heart ultrasound images to find people who may have undiagnosed fatty liver disease or cirrhosis. About 2,000 adults will have their heart scans checked by the AI. If the AI flags them as high ri…

This study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo for 12 months. Researchers will measure changes in a blood test that pr…

This study looks at whether adding a mild electrical stimulation device (TENS) to a Mediterranean diet can help people with nonalcoholic fatty liver disease feel less hungry and improve their liver health. Fifty adults aged 35-45 with fatty liver will be split into two groups: on…

This study tests whether an 8-week home-based high-intensity interval training (HIIT) program, done on a stationary bike and supervised remotely, can reduce liver fat and improve other health measures in 54 adults aged 35-65 with metabolic dysfunction-associated fatty liver disea…

This study looks at how eating a high-fat or high-carb breakfast changes fat levels in the blood over 8 hours. Researchers will compare results among people with conditions like diabetes, fatty liver, or kidney disease, as well as healthy volunteers. Participants will have two ov…

This study investigates how the experimental cancer drug atirmociclib is processed by the body in people with mild, moderate, or severe liver disease compared to those with healthy livers. Participants receive a single oral dose of the drug, and blood samples are taken over time …

This French study will collect medical data and biological samples from 800 people with autoimmune liver diseases. Researchers hope to identify new markers that explain why some patients respond well to treatment while others do not. The goal is to better understand the immune me…

This study looks at two types of liver disease — autoimmune hepatitis and non-alcoholic fatty liver disease — to see if fats in blood cells and tiny particles called extracellular vesicles differ between them. Researchers will collect blood samples from 24 adults and analyze thes…

This phase 1 trial investigates how mild, moderate, and severe liver impairment affects the way the body processes a single inhaled dose of treprostinil palmitil, a drug used for certain lung conditions. The study enrolls about 30 adults with varying levels of liver function and …

This study will check if certain blood-based inflammation markers are linked to fatty liver disease (MASLD) in 100 adults. Participants will have their blood tested and their liver health assessed. The goal is to better understand the role of inflammation in this condition, not t…

This study looks at how HIV might change the way the body handles fats in the liver, leading to fatty liver disease. Researchers will collect one blood sample from 120 adults: people with HIV and fatty liver, people without HIV but with fatty liver, and healthy controls. By analy…

This study tests new MRI techniques to measure blood flow and tissue details in the liver. Researchers will scan 110 people, including healthy volunteers and those with chronic liver disease or fibrosis, to see if these scans can reliably detect liver damage. The goal is to devel…

This study will compare meal timing habits between 400 participants, including new mothers and people with fatty liver disease, along with healthy controls. Participants will complete diet diaries and questionnaires, with some undergoing additional tests like blood sugar monitori…

This study will check how often muscle loss (sarcopenia) happens in 120 adults with metabolic fatty liver disease. Researchers will also see if muscle loss is linked to more severe liver scarring. The goal is to better understand the connection, not to test a new treatment.

This early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…

This study looks at whether lifestyle changes can reduce the risk of liver cancer in people already at high risk. Researchers will track changes in bile acids, gut bacteria, and liver health in 90 adults aged 50-90. The goal is to see if simple adjustments can make a lasting diff…

This observational study in Mexico will follow 30 adults already taking tirzepatide for conditions like diabetes or obesity. Researchers will use MRI scans of the knees, CT scans of the heart, and body composition tests to see how the drug affects cartilage, heart fat, and overal…

This study will check if a routine blood measure called mean platelet volume (MPV) can predict acute coronary syndrome (heart attack or unstable angina) in people with metabolic dysfunction-associated steatotic liver disease (MASLD). Researchers will compare MPV levels between 60…

This early-stage study looks at how a single 25 mg dose of VC005 tablets behaves in people with mild or moderate liver impairment compared to healthy volunteers. The goal is to measure drug levels and safety. 24 participants will take one dose and be monitored closely.

This study will follow 1,000 adults who have liver or bile duct surgery at one hospital in Italy. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand what affects recovery and long-term health after these opera…

This early-stage study will give a single dose of MDR-001, a GLP-1 receptor agonist tablet, to 32 people: some with mild or moderate liver impairment and some with healthy livers. Researchers want to see how the drug moves through the body and if it is safe in people with liver i…

This study follows 700 adults with fatty liver disease (MASLD) for three years to see if liver fat measured by ultrasound is linked to early heart problems. Participants get heart scans and checkups every 6 to 12 months. The goal is to find better ways to predict heart attacks, s…

This early-stage study looks at how the drug anecatibin fumarate is processed in the body of people with and without liver problems. It will include 24 adults with lung cancer. The goal is to understand safety and drug levels, not to test if the drug works.

This study tests whether two different ultrasound machines can accurately measure liver stiffness and inflammation in people with fatty liver disease. About 95 to 100 adults will take part, including healthy liver donors and patients with fatty liver. The goal is to see if these …

This study looks at whether certain blood test results (hs-CRP, triglycerides, and glucose) can help identify liver scarring in people with non-alcoholic fatty liver disease (NAFLD). Researchers will observe 96 adults who have NAFLD and check their blood markers alongside liver s…

This early-stage study looks at how the drug GS1-144 moves through the bodies of women with and without liver problems. About 24 women aged 18 to 70 will take part. The goal is to measure drug levels and see if liver function affects them. No treatment is being tested.

This study will check how often fatty liver disease and liver scarring happen in adults with type 1 diabetes or LADA in Quebec. About 100 participants will get a special liver scan (FibroScan) during one visit. The goal is to find hidden liver problems that current checkups might…

This study looks at how a 12-week exercise program (strength and aerobic training twice a week) affects liver fat, inflammation, and scarring in people with metabolic fatty liver disease. It compares results between older adults (70+) and middle-aged adults (40-60), as well as be…

This early-stage study looks at how the drug buagafuran (AF-5) behaves in people with liver impairment compared to those with normal liver function. Twenty-four adults will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor safety. The …

This study looks at 200 adults with fatty liver disease to find out how many are also obese. It will also describe the health details of patients who have fatty liver but are not overweight. The goal is to better understand the different types of fatty liver disease.

This study will examine whether a specific gut bacterium, Ruminococcus gnavus, and the chemicals it produces are linked to metabolic dysfunction-associated fatty liver disease (MAFLD). Researchers will compare 200 healthy adults and those with MAFLD to understand the connection. …

This study aims to create an artificial intelligence (AI) system that can combine medical images (like CT and MRI scans) with patient records and lab results to help doctors more accurately diagnose diseases of the liver, gallbladder, and pancreas. The researchers will use data f…

This study aims to create detailed computer models, or 'virtual twins,' of people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). By analyzing data from over 7,700 adults, researchers hope to better understand how the disease progresses and predict who migh…

This study looks at how the drug hydronidone moves through the body in people with different levels of liver function. Thirty adults with either normal liver function or varying degrees of liver impairment will take a single dose of the drug. The goal is to understand how liver h…

This study looks at how lowering insulin levels changes the way the liver makes sugar and fat. Researchers will give 36 overweight or obese adults with insulin resistance and fatty liver disease two different insulin infusions—one that keeps insulin high and one that lowers it by…

This study tests whether an electronic decision-support system can help primary care doctors and specialists better manage patients with metabolic-dysfunction associated steatotic liver disease (MASLD). The tool will prompt doctors to refer high-risk patients to liver specialists…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will test whether a special ultrasound technique can measure liver stiffness and fat as accurately as MRI in people with fatty liver disease. Researchers will compare results from both imaging methods in 145 healthy volunteers and patients. The goal is to find a simple…

This study will screen up to 10,000 adults aged 18-75 who are overweight or have metabolic issues like high blood sugar or cholesterol. Researchers will use questionnaires, blood tests, and liver ultrasounds to find out how common fatty liver disease is and what factors increase …

This study will check 200 adults with metabolic fatty liver disease for Helicobacter pylori infection using a stool test. The goal is to find out how common H. pylori is in this group. If a link is confirmed, it may open the door to new ways to manage fatty liver disease by treat…

This early-stage study tests the safety and tolerability of a new drug called QL2401 in 70 healthy Chinese adults aged 18 to 45. Participants receive either the drug or a placebo to see how the body handles it. The goal is to gather initial safety data before testing in people wi…

This study looks at stored liver biopsy samples from 30 people with MASH (a fatty liver disease) to see if a protein test can predict who will develop liver cancer within 15 years. Half of the participants later got liver cancer, and half did not. Researchers will compare the pro…

This study will screen 200 adults with metabolic fatty liver disease (MAFLD) for high uric acid levels. Researchers will measure uric acid and liver function at diagnosis and after 6 months. The goal is to understand how common high uric acid is in these patients and whether it c…

This study will look at 80 pregnant women with signs of liver issues, such as high liver enzymes or bilirubin, to find out which liver disorders are most common and how they affect both mother and baby. Researchers will track changes in liver health over time using blood tests an…

This study looks at 100 adults who had their gallbladder removed at least 5 years ago to see if they are more likely to develop fatty liver disease (MAFLD). Researchers will check for fat in the liver and measure blood markers. The goal is to understand if gallbladder removal lea…

This study will compare two types of liver transplants: auxiliary (where part of the patient's own liver is left in place) and living donor (where a portion of a donor's liver is used). Researchers will track 100 patients to see which approach leads to better survival, fewer comp…

This study will follow 100 adults with chronic liver disease who are hospitalized for sudden worsening of their condition. Researchers will track organ failure, recovery, and whether patients need a liver transplant or die within 6 months. The goal is to better understand how the…

This study will compare a new handheld device to the standard iLivTouch system for measuring liver stiffness and fat in 224 adults with chronic liver disease. Participants will be tested with both devices while lying down and sitting. The goal is to see if the handheld device is …

This study will track 100 liver transplant patients to see how many develop a new fatty liver condition called MASLD after their transplant. Researchers will also look for risk factors like weight, diabetes, and cholesterol levels. The goal is to better understand this common but…

This study will test whether ultrasound can measure liver fat as accurately as MRI in 30 adults with fatty liver disease. Participants will have both an ultrasound and an MRI scan. The goal is to see if ultrasound, which is cheaper and faster, could be a reliable alternative for …

This study will examine the connection between high uric acid levels (hyperuricemia) and non-alcoholic fatty liver disease (NAFLD) in 111 obese adults. Researchers will use blood tests, ultrasound, and FibroScan to measure uric acid, liver fat, and liver scarring. The goal is to …

This study will look at 150 infants and children aged 1 month to 4 years who are admitted to a hospital gastroenterology unit with a gastrointestinal disease. The goal is to find out how common electrolyte disturbances (like low sodium or potassium) are in these children. By meas…